

• **Pregnancy:** to use a nonhormonal form of birth control while taking this product if using contraceptives

• If dose is missed, to take as soon as remembered up to 1 hr before next dose; not to double dose; to take with food

• To report symptoms of hyperglycemia, bleeding, abdominal pain, yellowing of skin, eyes

• **Phenylketonuria:** that powder contains phenylalanine

• To advise all providers of this product; to advise prescriber of all OTC products, prescription products, or herbal products taken

RARELY USED

neomycin (Rx)

(nee-oh-mye'sin)

Neo-Fradin

Func. class.: Antiinfective—aminoglycoside

USES: Severe systemic infections of CNS, respiratory, GI, urinary tract, eye, bone, skin, soft tissues; hepatic coma, preoperatively to sterilize bowel, infectious diarrhea caused by enteropathogenic *E. coli*, *Enterobacter* sp., *Escherichia coli*, *Klebsiella* sp. May be effective for *Acinetobacter* sp., *Bacillus anthracis*, *Citrobacter* sp., *Haemophilus influenzae* (beta-lactamase negative), *Haemophilus influenzae* (beta-lactamase positive), *Neisseria* sp., *Proteus mirabilis*, *Proteus vulgaris*, *Providencia* sp., *Salmonella* sp., *Serratia* sp., *Shigella* sp., *Staphylococcus aureus* (MSSA), *Staphylococcus epidermidis*

CONTRAINDICATIONS: Infants, children, bowel obstruction (oral use), severe renal disease, hypersensitivity, GI disease

Precautions: Dehydration, geriatric patients, respiratory insufficiency

Black Box Warning: Hearing impairment, neuromuscular disease, renal disease

DOSAGE AND ROUTES

Hepatic encephalopathy

• **Adult:** PO 4-12 g/day in divided doses q6hr × 5-6 days

• **Child:** PO 50-100 mg/kg/day in divided doses q6hr × 5-6 days

Preoperative intestinal antisepsis

• **Adult:** PO 1 g/hr × 4 hr, then 1 g q4hr for remaining 24 hr

⚠ HIGH ALERT

RARELY USED

nepafenac ophthalmic

See Appendix B

neratinib

(ne-ra'-ti-nib)

Nerlynx

Func. class.: Antineoplastic

Chem. class.: Protein kinase inhibitors

ACTION: It is an irreversible inhibitor of the epidermal growth factor receptor (EGFR) and the human epidermal receptor type 2 (HER2) and HER4. It is a protein kinase inhibitor

USES: For the extended adjuvant treatment of early-stage HER2-positive breast cancer after completion of adjuvant trastuzumab

CONTRAINDICATIONS: Hypersensitivity

Precautions: Breastfeeding, contraception requirements, geriatric patients, hepatic disease, hepatotoxicity, infertility, pregnancy, pregnancy testing, reproductive risk

DOSAGE AND ROUTES

For the extended adjuvant treatment of early-stage HER2-positive breast cancer after completion of adjuvant trastuzumab-based therapy

• **Adult:** PO 240 mg/day with food, × 1 yr